PS-5505
- Product Name
- PS-5505
- CAS No.
- 2409964-23-2
- Chemical Name
- PS-5505
- Synonyms
- PS-5505;PXS5505 HCl;LOX-IN-3 dihydrochloride;LOX-IN-3 dihydrochloride, 10 mM in DMSO;(Z)-3-Fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine dihydrochloride;lysyl,LOXIN3 dihydrochloride,Inhibitor,oxidase,MAO,Monoamine Oxidase,fibrosis,inhibit,LOXL2,LOX IN 3 dihydrochloride
- CBNumber
- CB28674300
- Molecular Formula
- C13H14ClFN2O2S
- Formula Weight
- 316.78
- MOL File
- 2409964-23-2.mol
PS-5505 Property
- storage temp.
- Store at -20°C
- solubility
- DMSO : 100 mg/mL (283.09 mM; Need ultrasonic)
- form
- Solid
- color
- Off-white to light yellow
- InChI
- InChI=1S/C13H13FN2O2S.ClH/c14-11(6-7-15)9-19(17,18)12-5-1-3-10-4-2-8-16-13(10)12;/h1-6,8H,7,9,15H2;1H/b11-6-;
- InChIKey
- WEFLTRNHDTUNKA-AVHZNCSWSA-N
- SMILES
- S(C1=CC=CC2C=CC=NC1=2)(=O)(=O)C/C(/F)=C/CN.Cl
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
P501Dispose of contents/container to..…
PS-5505 Chemical Properties,Usage,Production
Uses
LOX-IN-3 dihydrochloride is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 dihydrochloride can be used for fibrosis, cancer and angiogenesis research[1].
Biological Activity
LOX-IN-3 dihydrochloride is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 dihydrochloride can be used for fibrosis, cancer and/or angiogenesis research[1]. LOX-IN-3 (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC50 values of <10 μM and <1 μM, respectively. LOX-IN-3 is less active against SSAO/VAP-1 and MAO-B activities[1]. In young male Wistar rats, a single high (30 mg/kg) dose of LOX-IN-3 (Compound 33) completely abolishes lysyl oxidase activity. While plasma concentrations of LOX-IN-3 are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta)[1].In a 14-day unilateral ureteric obstruction (UUO) model, LOX-IN-3 (Compound 33, 10 mg/kg daily; orally) treatment increases kidney weight and thickness and reduces the area of fibrosis as measured by Picrosirius Red[1].In BALB/c mice bearing hepatic fibrosis, LOX-IN-3 (Compound 33, 20 mg/kg daily, i.p.) treatment significantly reduces liver fibrosis. At the end of week 4 a mouse breast cancer cell line (4tl) is injected orthotopically. LOX-IN-3 (Compound 33) treatment significantly reduces liver fibrosis, collagen cross-links and the metastatic load in the liver[1].
in vivo
LOX-IN-3 dihydrochloride monohydrate (Compound 33) (30 mg/kg; orally; once) inhibits lysyl oxidase activity in rats[1].
LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model[1].
LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice[1].
| Animal Model: | Male Wistar rats[1] |
| Dosage: | 30 mg/kg |
| Administration: | Oral administration, single dose |
| Result: | Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta). |
| Animal Model: | Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage, daily for 14 days |
| Result: | Increased kidney weight and thickness and reduced the area of fibrosis. |
| Animal Model: | C57Bl/6 mice, Bleomycin-induced lung fibrosis model |
| Dosage: | 15 mg/kg |
| Administration: | Oral gavage, daily for 21 days |
| Result: | Significantly reduced the Ashcroft score and the lung weight. |
References
[1]. Alison Dorothy Findlay, et al. Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof. WO2020024017A1.
PS-5505 Preparation Products And Raw materials
Raw materials
Preparation Products
PS-5505 Suppliers
- Tel
- 021-QQ：65489617 15618227136
- Fax
- 21-5161 9052
- Sales@ATKchemical.com
- Country
- China
- ProdList
- 9550
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7055
- Advantage
- 58
- Tel
- 025-83697070 13913916777
- Fax
- +86-25-83453306
- info@chemlin.com.cn
- Country
- China
- ProdList
- 16059
- Advantage
- 64
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4827
- Advantage
- 55
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- 0595-22008920; 18120708884
- 393612455@qq.com
- Country
- China
- ProdList
- 255
- Advantage
- 58
- Tel
- +86-29-81139210 +86-18192627656
- Fax
- +86-29-88380327
- 1059@dideu.com
- Country
- China
- ProdList
- 3590
- Advantage
- 58
- Tel
- 400-1647117 13681763483
- product02@bidepharm.com
- Country
- China
- ProdList
- 59936
- Advantage
- 58
- Tel
- 13549236410
- sales@invivochem.cn
- Country
- China
- ProdList
- 6753
- Advantage
- 58
View Lastest Price from PS-5505 manufacturers
- Product
- PS-5505 2409964-23-2
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 98%
- Supply Ability
- 1000kg
- Release date
- 2025-11-26
- Product
- PS-5505 2409964-23-2
- Price
- US $1.00-4.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 200000KG
- Release date
- 2025-09-11